Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan OKs FY2022 Budget Guidelines, 660 Billion Yen Cap for Social Security Cost Rise
July 8, 2021
- MHLW Announces 1st Revision of Dyslipidemia Drug Development Guidelines in 30 Years
July 8, 2021
- Label Revisions Ordered for Myocarditis/Pericarditis Risks of Pfizer, Moderna’s COVID Vaccines
July 8, 2021
- MHLW’s COVID-19 Guide Recommends against Camostat after Trial Failures
July 7, 2021
- Health Minister Hints at Priority Vaccine Supply to Municipalities Making Headway
July 7, 2021
- MHLW Ups Ante for Regulatory Reviews of Jointly Developed Generics
July 7, 2021
- Leigh Syndrome Drug PTC743 Gets Orphan Status
July 6, 2021
- Draft Revision of MHLW’s Distribution Guidelines Stresses Compliance with Antitrust Act
July 5, 2021
- Govt to Provide Vaccines for All Workplace Programs Requested
July 5, 2021
- MHLW Urges Wholesalers to Strictly Enforce Legal Compliance after Bid-Rigging Ruling
July 2, 2021
- Sakigake Tag Revoked for Eisai’s E7090 after Pemazyre Approval
July 1, 2021
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- MHLW to Start Study on US, European Schemes on ADR Evaluation
June 29, 2021
- MHLW Extends Maximum Biz Suspension Period to 180 Days in All Prefectures
June 29, 2021
- Japan Issues Guidelines on Drug Delivery by Drones; Operation Plan, Quality Assurance Required
June 28, 2021
- Japan Allots 33 Million Moderna Shots to Companies, 17 Million to Local Govts: Minister
June 28, 2021
- PMDA Reviewing New Safety Risk for Evenity, 13 Other APIs
June 28, 2021
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
- Japan to Stop Accepting Requests for Moderna Vaccines for Workplace Inoculations
June 24, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…